Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations

Fineline Cube Mar 5, 2026
Company Drug

Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss

Fineline Cube Mar 5, 2026
Company Drug

Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer

Fineline Cube Dec 19, 2023

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...

Company Drug

Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study

Fineline Cube Dec 19, 2023

Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...

Company Drug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

Fineline Cube Dec 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...

Company Drug

Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar

Fineline Cube Dec 19, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals

Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial

Fineline Cube Dec 18, 2023

Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...

Company Drug

FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer

Fineline Cube Dec 18, 2023

Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...

Medical Device Policy / Regulatory

China Releases Emergency Use Rules for Medical Devices Amid Public Health Emergencies

Fineline Cube Dec 18, 2023

The National Medical Products Administration (NMPA), National Health Commission (NHC), and Chinese Center for Disease...

Company Deals

Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output

Fineline Cube Dec 18, 2023

Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a...

Company Deals

Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round

Fineline Cube Dec 18, 2023

Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence...

Company Drug

Bio-Thera Solutions Gets NMPA Green Light for PD-1 Inhibitor BAT1308 in Endometrial Cancer

Fineline Cube Dec 18, 2023

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Deals

Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production

Fineline Cube Dec 18, 2023

Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry,...

Company

Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau

Fineline Cube Dec 18, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China,...

Company Deals

Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence

Fineline Cube Dec 18, 2023

Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with...

Company Drug

Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease

Fineline Cube Dec 18, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s...

Company Drug

InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study

Fineline Cube Dec 18, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...

Company Drug

MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma

Fineline Cube Dec 15, 2023

The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...

Company Deals

Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response

Fineline Cube Dec 15, 2023

German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health...

Company Drug

3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient

Fineline Cube Dec 15, 2023

3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first...

Company Deals

BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery

Fineline Cube Dec 15, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics...

Company Deals

Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics

Fineline Cube Dec 15, 2023

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...

Posts pagination

1 … 393 394 395 … 630

Recent updates

  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
  • Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss
  • Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff
  • Gilead Foundation Commits $12 Million to Community Health Worker HIV Prevention Initiative – 33 Organizations Across 15 U.S. Jurisdictions
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Company Drug

Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations

Company Drug

Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss

Company

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.